×
More Charts Below
OncoCyte Total Liabilities and Share Holders Equity 2014-2024 | OCX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Recent Trends
OncoCyte total liabilities and share holders equity from 2014 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
Quarterly Chart
Quarterly - YOY Change
Annual
Annual % Change
Related Stocks
Company Name
Market
Cap
Danaher (DHR)
$133.5B
Elevance Health (ELV)
$96.1B
CVS Health (CVS)
$84.8B
Cencora (COR)
$55.6B
DiDi Global (DIDIY)
$20.3B
Natera (NTRA)
$20B
BioMerieux (BMXMF)
$15.6B
Solventum (SOLV)
$11.5B
ICON (ICLR)
$11.3B
EUROFINS SCIENT (ERFSF)
$11.1B
Revvity (RVTY)
$11B
CochLear (CHEOY)
$10.9B
Avantor (AVTR)
$10.3B
Doximity (DOCS)
$9.9B
Viatris (VTRS)
$9B
Medpace Holdings (MEDP)
$9B
Sonic Healthcare (SKHHY)
$7.7B
HealthEquity (HQY)
$7.3B
Charles River Laboratories (CRL)
$5.2B
Amplifon S.p.A (AMFPF)
$4.3B
Bausch + Lomb (BLCO)
$4.3B
Alignment Healthcare (ALHC)
$3.5B
Sotera Health (SHC)
$3B
BrightSpring Health Services (BTSG)
$2.9B
Organon (OGN)
$2.9B
Surgery Partners (SGRY)
$2.7B
GeneDx Holdings (WGS)
$2.7B
Concentras Parent (CON)
$2.6B
Progyny (PGNY)
$1.8B
Ardent Health Partners (ARDT)
$1.8B